Response to Crizotinib After Entrectinib Resistance in <i>ROS1</i>-Rearranged, <i>MET</i>-Amplified Lung Adenocarcinoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 39374479.
- Also identified by DOI 10.1200/PO-24-00394.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.
Medical subject headings
- Crizotinib
- Proto-Oncogene Proteins
- Indazoles
- Protein-Tyrosine Kinases
- Proto-Oncogene Proteins c-met
- Lung Neoplasms
- Benzamides
- Adenocarcinoma of Lung
- Drug Resistance, Neoplasm